ストックスクリーナーアプリを入手
152.75
2.56%
3.82
アフターアワーズ：
151.21
-1.54
-1.01%
前日終値:
$148.93
開ける：
$149.03
24時間の取引高:
1.02M
Relative Volume:
1.09
時価総額：
$7.52B
収益：
$4.06B
当期純損益:
$413.08M
株価収益率:
19.07
EPS:
8.01
ネットキャッシュフロー:
$560.48M
1週間 パフォーマンス:
-8.80%
1か月 パフォーマンス:
-4.17%
6か月 パフォーマンス:
-0.81%
1年 パフォーマンス:
-21.39%
1日の値動き範囲:
$149.03
$154.01
1週間の範囲:
$145.99
$162.72
52週間の値動き範囲:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
名前
Charles River Laboratories International Inc
セクター
電話
781-222-6000
住所
251 BALLARDVALE ST, WILMINGTON, MA
CRL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
152.75 | 7.32B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
477.41 | 173.97B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.72 | 143.61B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
652.27 | 52.65B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
117.32 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.91 | 30.58B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-09 | アップグレード | Citigroup | Neutral → Buy |
| 2025-05-23 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | アップグレード | TD Cowen | Hold → Buy |
| 2025-05-08 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-03-21 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-04 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-03 | アップグレード | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | ダウングレード | UBS | Buy → Neutral |
| 2024-11-18 | ダウングレード | CLSA | Hold → Underperform |
| 2024-11-07 | アップグレード | CLSA | Underperform → Hold |
| 2024-10-23 | 開始されました | CLSA | Underperform |
| 2024-10-14 | 開始されました | Redburn Atlantic | Sell |
| 2024-10-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-01 | ダウングレード | Citigroup | Neutral → Sell |
| 2024-08-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | ダウングレード | Argus | Buy → Hold |
| 2024-06-07 | 開始されました | Mizuho | Neutral |
| 2024-06-06 | 開始されました | Goldman | Buy |
| 2024-02-15 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-09-13 | 開始されました | TD Cowen | Market Perform |
| 2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-02-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-12 | ダウングレード | Jefferies | Buy → Hold |
| 2022-09-30 | アップグレード | Jefferies | Hold → Buy |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-08-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 開始されました | Guggenheim | Neutral |
| 2022-04-25 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-07 | 開始されました | Stephens | Overweight |
| 2022-02-17 | 繰り返されました | BofA Securities | Buy |
| 2022-02-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-02-17 | 繰り返されました | Deutsche Bank | Buy |
| 2022-02-17 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-17 | 繰り返されました | UBS | Buy |
| 2021-08-05 | 再開されました | Credit Suisse | Neutral |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-09-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-07-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-05-13 | アップグレード | UBS | Neutral → Buy |
| 2020-04-21 | ダウングレード | Jefferies | Buy → Hold |
| 2020-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 開始されました | Deutsche Bank | Buy |
| 2020-02-18 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | アップグレード | Goldman | Neutral → Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-10-18 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 開始されました | SVB Leerink | Outperform |
| 2019-04-30 | 再開されました | Evercore ISI | Outperform |
| 2018-12-14 | 開始されました | Deutsche Bank | Buy |
| 2018-10-09 | 開始されました | UBS | Neutral |
| 2018-08-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Charles River Laboratories International Inc (CRL) 最新ニュース
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - FinancialContent
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View - MSN
Interpreting Charles River (CRL) International Revenue Trends - Yahoo Finance
Charles River Laboratories International Inc. Recovery Linked to Earnings SurprisePattern Alert With ROI Driven Strategy Shared - metal.it
Stock Analysis | Charles River Laboratories International OutlookMixed Signals Amid Earnings Watch - AInvest
Charles River Laboratories Reports Q2 2025 Earnings - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MSN
Charles River Laboratories International 2025 Q2 Earnings Misses Targets as Net Income Drops 44% - AInvest
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript - Insider Monkey
Charles River Laboratories International Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Charles River Laboratories Q2 2025 Earnings Preview - MSN
Charles River Laboratories International Q2 2025 Earnings Call Transcript - MarketBeat
Charles River Laboratories International 2025 Q2 Earnings Beats Expectations as Net Income Drops 44.1% - AInvest
Charles River: Q2 Earnings Snapshot - Milford Mirror
Charles River Labs Reports Mixed Q2 Earnings Call - TipRanks
Charles River Laboratories Shares Drop 10.25% Despite 49.73% Volume Surge Ranking 339th in Market Activity as Order Cancellations Weigh on Investor Sentiment - AInvest
Charles River (CRL) Q2 EPS Jumps 11% - The Globe and Mail
Charles River (CRL) Q2 EPS Jumps 11% - The Motley Fool
Charles River Labs stock price target raised to $175 by BofA Securities - Investing.com India
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - 富途牛牛
Charles River: Margin Fears Outweigh Solid Q2 (NYSE:CRL) - Seeking Alpha
Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $185 From $180 - MarketScreener
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2 - Yahoo Finance
Charles River Labs Q2 2025 slides: Beats expectations, raises guidance amid stabilizing demand - Investing.com Canada
Charles River Laboratories Announces Second-Quarter 2025 Results - BioSpace
Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Updated - MarketScreener
Charles River Laboratories Reports Q2 2025 Revenue of $1.03 Bill - GuruFocus
Charles River Labs soars 6.9% after crushing Q2 earnings expectations By Investing.com - Investing.com South Africa
Charles River Labs soars 6.9% after crushing Q2 earnings expectations - Investing.com
Charles River Laboratories earnings beat by $0.62, revenue topped estimates - Investing.com Canada
Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
How volatile is Charles River Laboratories International Inc. stock compared to the marketBuild wealth steadily with proven strategies - Jammu Links News
Charles River Laboratories International Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - Jammu Links News
What is Charles River Laboratories International Inc. company’s growth strategyBuild a winning investment portfolio - Jammu Links News
Is it the right time to buy Charles River Laboratories International Inc. stockIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Charles River Laboratories International Inc. stockRobust investment performance - Jammu Links News
How strong is Charles River Laboratories International Inc. company’s balance sheetMarket-leading profit generation - Jammu Links News
What are Charles River Laboratories International Inc. company’s key revenue driversAchieve breakthrough gains with expert advice - Jammu Links News
What makes Charles River Laboratories International Inc. stock price move sharplyMaximize returns with strategic trading plans - Jammu Links News
What institutional investors are buying Charles River Laboratories International Inc. stockFree Smart Trading Workshop - jammulinksnews.com
Charles River Laboratories International, Inc. (NYSE:CRL) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Should I hold or sell Charles River Laboratories International Inc. stock in 2025Post Market Planner For Smart Trading - Jammu Links News
Charles River Laboratories International Inc (CRL) 財務データ
収益
当期純利益
現金流量
EPS
2.23%
大文字化:
|
ボリューム (24 時間):